Compare · LITS vs NVO
LITS vs NVO
Side-by-side comparison of Lite Strategy Inc. (LITS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LITS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 4779.3x LITS ($36.3M).
- LITS has been more active in the news (6 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for LITS).
- Company
- Lite Strategy Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $36.3M
- $173.66B
- 1M return
- +8.02%
- -
- 1Y return
- -38.93%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2003
- News (4w)
- 6
- 4
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LITS
- Lite Strategy Marks 15 Years of Litecoin with Launch of "Proof of Time" Public Industry Archive
- SEC Form EFFECT filed by Lite Strategy Inc.
- Lite Strategy Reports Fiscal Year 2026 Financial Results
- SEC Form S-8 filed by Lite Strategy Inc.
- SEC Form S-3 filed by Lite Strategy Inc.
- SEC Form 10-K filed by Lite Strategy Inc.
- Lite Strategy to Present at the 28th Annual H.C. Wainwright Global Investment Conference in New York
- Lite Strategy Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share
- Lite Strategy Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank